Detalhe da pesquisa
1.
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
Lancet
; 397(10269): 119-127, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33422245
2.
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Lancet Infect Dis
; 23(8): 974-982, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37127045
3.
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Lancet Infect Dis
; 23(8): 965-973, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37127047
4.
What Constitutes Protective Immunity Following Yellow Fever Vaccination?
Vaccines (Basel)
; 9(6)2021 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34207358
5.
Factors influencing the implementation of cardiovascular risk scoring in primary care: a mixed-method systematic review.
Implement Sci
; 15(1): 57, 2020 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32690051
6.
Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda.
Wellcome Open Res
; 4: 182, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31984244